MarketVIEW Hospital / AMR Diseases  ·  May 2019 edition

Acinetobacter baumannii
Vaccines Forecast

Acinetobacter baumannii remains a WHO critical priority pathogen, and carbapenem-resistant strains (CRAB) alone caused an estimated 50,000 to 100,000 deaths attributable to antimicrobial resistance in 2019, with mortality in CRAB infections reaching up to 70% among critically ill, ventilated ICU patients. Since VacZine Analytics last published on this market in May 2019, when every vaccine candidate remained preclinical, the field has reported its first human data: ALOPEXX's PNAG-based AV0328 has completed a well-tolerated Phase 1 first-in-man trial, and Vaxdyn's trivalent Gram-negative candidate is targeting its own first proof of concept in humans. This is a comprehensive, wide geography commercial assessment of the Acinetobacter baumannii vaccine opportunity, drawing on VacZine Analytics' long standing, independent authority in hospital-acquired and antimicrobial-resistant disease vaccine markets.

CRAB Mortality Up to 70% AV0328: First-in-Human Phase 1 Complete Major Western Hospital Markets WHO Critical Priority Pathogen (Since 2017)
Product catalogue
VAMV070
May 2019 edition

Format
PDF (~100 slides) + Excel model
Markets modelled
Major Western hospital markets
Scenarios
LO / BASE / HI deployment
Forecast horizon
To 2030
Approach
Patient-group targeting demand model
Base edition
May 2019
Availability
Syndicated / bespoke
1.27M
Deaths worldwide directly
attributable to bacterial AMR (2019)
50-100K
Deaths attributable to carbapenem-
resistant A. baumannii (CRAB) alone
Up to 70%
Mortality rate in CRAB infections,
versus ~25% for susceptible strains
0
Licensed A. baumannii vaccines
available today
Disease background

A critical priority pathogen, quantified more precisely than ever

This review sets out the current disease background, global AMR burden and R&D competitive landscape for Acinetobacter baumannii, drawing on the latest WHO and GRAM surveillance data.

WHO / GRAM 2025-2026 AMR surveillance update

Pathogen overview - Acinetobacter baumannii

Acinetobacter baumannii (AB), of the genus Acinetobacter, is a ubiquitous, aerobic Gram-negative bacillus that preferentially colonises aquatic and hospital environments. Because of its high propensity for antimicrobial resistance, the bacterium has been a WHO critical (formerly "Priority No 1") pathogen since 2017, a designation WHO reaffirmed in its 2024 bacterial priority pathogens list. AB is associated with around 1 to 2% of hospital-acquired infections, where colonisation is linked to an increased risk of hospital death. Patients usually affected are the critically ill and immunocompromised, often admitted to intensive care and receiving mechanical ventilation. In these settings, AB pneumonia can carry mortality rates above 50%, and infections are frequently difficult to treat with current antibiotics, particularly multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) forms. AB-resistant infections dramatically increase hospital length of stay and economic cost.

The scale of that resistance burden has since been quantified more precisely. The Global Research on Antimicrobial Resistance (GRAM) project's landmark analysis of 2019 data attributed 1.27 million deaths worldwide directly to bacterial antimicrobial resistance, with six pathogens, including A. baumannii, each responsible for more than 250,000 AMR-associated deaths. Carbapenem-resistant A. baumannii (CRAB) specifically caused an estimated 50,000 to 100,000 deaths attributable to AMR in 2019, and mortality in CRAB infections has been recorded as high as 70%, compared with around 25% for susceptible strains. In the United States alone, the CDC estimates around 8,500 CRAB cases and 700 associated deaths each year. Two new antibiotics, cefiderocol and sulbactam-durlobactam, have reached the market since VacZine Analytics' 2019 edition, and several further candidates, including zosurabalpin, BV-100, WCK-4234 and OMN6, are in later-stage clinical trials, but rising resistance continues to erode the treatment options available for the sickest patients.

Against that backdrop, immunologic approaches such as prophylactic vaccines and monoclonal antibodies remain a central focus for a genuinely durable solution. When VacZine Analytics last published on this market in May 2019, every vaccine candidate under active development, including those from ALOPEXX, Vaxdyn and Aridis Pharmaceuticals, remained preclinical. The field has since reported its first human clinical data: ALOPEXX's PNAG-targeted candidate AV0328 has completed a Phase 1, first-in-man trial that found the vaccine well tolerated, with no serious adverse events, and capable of inducing antibodies that killed a wide range of PNAG-expressing pathogens. Vaxdyn, a CARB-X-backed programme developing a single trivalent vaccine against A. baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae, has targeted its own first proof of concept in humans. Aridis Pharmaceuticals' AR-401 monoclonal antibody programme against A. baumannii remains in preclinical development as of its most recent corporate update.

2026 1.27M AMR-attributable deaths worldwide (2019)  |  CRAB: 50,000-100,000 deaths  |  CRAB mortality up to 70%  |  AV0328 Phase 1 complete  |  still no licensed vaccine
Product & competitor landscape

From all-preclinical to first human data, against a hardening resistance problem

Every Acinetobacter baumannii vaccine candidate was preclinical when VacZine Analytics last published this market in May 2019. The field has since reported its first published human trial data, even as carbapenem-resistant strains keep raising the treatment stakes.

  • ALOPEXX Vaccine LLCPhase 1 complete, first-in-man
    AV0328 PNAG-targeted, broadly cross-protective
    Completed a Phase 1, first-in-man trial that found the vaccine well tolerated with no serious adverse events, inducing antibodies capable of killing a wide range of PNAG-expressing pathogens, including A. baumannii. In September 2026, Alopexx set formal terms for an IPO on NYSE American (ticker ALPX), targeting roughly $30-33 million, with $6 million of proceeds earmarked specifically to fund a proof-of-concept study advancing AV0328 beyond its completed Phase 1 trial.
  • Vaxdyn (CARB-X-backed)€11m raised to fund Phase 1 (Sep 2026)
    Trivalent Gram-negative vaccine candidate Multivalent: A. baumannii, P. aeruginosa & K. pneumoniae
    A single trivalent vaccine directed against three priority Gram-negative pathogens, with first proof-of-concept human data targeted for the near term. In September 2026, Vaxdyn closed an €11 million financing round, led by Biovance Capital alongside Arcano Partners and the European Innovation Council (EIC) Fund, complemented by non-dilutive support from CARB-X and the EIC Accelerator, earmarked specifically to fund a Phase 1 clinical trial of its lead candidate, K-VAX, targeting Klebsiella pneumoniae and Acinetobacter baumannii.
  • Aridis PharmaceuticalsPreclinical (per most recent corporate update)
    AR-401 Monoclonal antibody programme
    A complementary immunologic, non-vaccine approach targeting A. baumannii, continuing in preclinical development.
  • WHO / GRAM / national surveillance networksActive AMR surveillance
    Global A. baumannii & CRAB resistance monitoring
    Ongoing tracking of carbapenem-resistant, MDR, XDR and PDR A. baumannii strains, reaffirmed as a WHO critical priority pathogen in its 2024 bacterial priority pathogens list, continues to inform vaccine target product profile design and market-access urgency.
Field inflection point
Phase 1

ALOPEXX's completion of a well-tolerated, first-in-man Phase 1 trial for AV0328 marks the first published human clinical data for an Acinetobacter baumannii-protective vaccine candidate since VacZine Analytics' 2019 edition, when every candidate in development remained preclinical. That progress arrives just as carbapenem-resistant A. baumannii mortality has been recorded as high as 70%, reframing the commercial case across the major Western hospital markets covered by this model. The VacZine Analytics model quantifies this opportunity under LO/BASE/HI pricing scenarios reflecting successive targeting of patient groups and specific subsets who would benefit most from vaccination.

Scope of analysis

Six analytical layers - one commercial picture

This is a genuinely comprehensive report with a wide geographic focus, spanning disease burden, current R&D status and scenario-based demand forecasting across major Western hospital markets to 2030.

Major Western hospital market forecast

Value ($m) and volume (million doses) forecasts to 2030 across major Western hospital and ICU markets.

Competitor & pipeline review

Full review of ALOPEXX's AV0328, Vaxdyn's trivalent candidate, Aridis' AR-401 and the wider immunologic R&D landscape.

TPP, launch timing & pricing

Target product profile, launch timeframe assumptions, pricing and market penetration estimates for successive patient-group targeting.

LO/BASE/HI scenario forecasts

Three deployment scenarios based on successive targeting of patient groups and specific at-risk subsets.

Disease burden & epidemiology

Global AMR-attributable mortality and CRAB-specific burden data updated through WHO/GRAM's most recent reporting.

Antimicrobial resistance & unmet need review

Assessment of MDR/XDR/PDR A. baumannii prevalence, the current antibiotic pipeline and the rationale for a vaccine approach.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the patient-group and scenario framework. Full volume/value outputs, pricing assumptions and patient-subset data are in the licensed model.

Market segmentGeographySectorVaccine statusRevenue scenario
ICU / mechanically ventilated patientsUS, EU & major Western marketsHospital/publicPre-licensureModelled
High-risk surgical & burn patientsUS, EU & major Western marketsHospital/privatePre-licensureModelled
Broader at-risk hospitalised populationUS, EU & major Western marketsHospital/publicPre-licensureModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAll geographiesAll sectorsAll scenarios$███m
Full model in the licensed workbook
Major Western hospital markets · to 2030 · LO/BASE/HI scenarios
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive summary presentation and a fully interactive forecast model, built for organisations evaluating the Acinetobacter baumannii vaccine opportunity across major Western hospital markets.

  • Executive summary presentation (~100 slides, PDF) - disease background, epidemiology, R&D status and full commercial assessment with supporting narrative and references
  • MS-Excel forecast model (55 worksheets) - value ($m) and volume (million doses) predictions to 2030 across major Western hospital markets
  • LO/BASE/HI deployment scenarios - three forecast scenarios based on successive targeting of patient groups and specific at-risk subsets
  • Competitor intelligence - ALOPEXX's AV0328, Vaxdyn's trivalent candidate, Aridis' AR-401 and the wider immunologic R&D landscape
  • Updated epidemiology module - WHO/GRAM 2025-2026 update covering AMR-attributable mortality, CRAB-specific burden and resistance trends
  • TPP & pricing justification - target product profile and commercial model assumptions with economic pricing justification for successive patient-group targeting
Target audience

Built for organisations weighing the Acinetobacter baumannii vaccine opportunity

Most valuable to teams evaluating the Acinetobacter baumannii vaccine market against their own pipeline, BD ambitions or investment thesis, now that a candidate has cleared human trials.

Vaccine & mAb developers

Positioning and commercial feasibility assessment for A. baumannii candidates at any stage, informed by AV0328's first-in-man Phase 1 data.

Corporate strategy & BD

Validate the size and structure of a still-open market with no incumbent vaccine, now that a candidate has cleared human trials.

Investors & analysts

Independent assessment of pipeline risk and commercial upside for due diligence on ALOPEXX, Vaxdyn, Aridis and future entrants.

Hospital & infection-control leadership

Demand modelling and patient-group risk classification to support ICU and hospital-acquired infection prevention planning.

Researchers & academia

Comprehensive epidemiology, antimicrobial resistance and immunologic R&D landscape for grant and translational research planning.

Market access & policy

Pricing benchmarks and access-pathway assumptions across major Western hospital and public health channels.

About this analysis · VAMV070

VacZine Analytics has tracked hospital-acquired and antimicrobial-resistant disease vaccine markets since our earliest editions, positioning us to reassess the Acinetobacter baumannii vaccine opportunity the moment the field's leading candidate reported its first published human trial data. This is a genuinely comprehensive analysis with a wide geographic focus spanning major Western hospital markets, and it has been well received by clients across the field for the depth of its epidemiology and patient-group targeting model. Few groups have followed this market as closely, and that recognised, independent expertise underpins everything in the analysis.

This May 2019 edition has been further refreshed to incorporate WHO and GRAM's most recent AMR data, confirming 1.27 million deaths worldwide directly attributable to bacterial antimicrobial resistance and 50,000 to 100,000 deaths specifically attributable to carbapenem-resistant A. baumannii, alongside ALOPEXX's Phase 1 trial results for AV0328 and Vaxdyn's advance toward first human proof of concept. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV070 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Acinetobacter baumannii analysis, a briefing call is included on request.